Organization Overview
Alternative names
abiraterone (zytiga) (1 trial)
alemtuzumab (campath) (1 trial)
allogeneic adipose derived mesenchymal stem cell (3 trials)
allogeneic hematopoietic stem cells (Hemacord) (2 trials)
autologous mesenchymal stem cells (1 trial)
azacitidine (vidaza) (1 trial)
belantamab mafodotin (TECVAYLI) (2 trials)
bortezomib (velcade) (3 trials)
brentuximab vedotin (adcetris) (1 trial)
carfilzomib (kyprolis) (1 trial)
cisplatin (platinol) (1 trial)
cyclophosphamide (cytoxan) (1 trial)
cyclosporine (sandimmune) (1 trial)
Adenocarcinoma (Phase 3)
Aggression (Phase 2)
Anemia (Phase 2)
Anus Neoplasms (Phase 2)
Aortic Valve Stenosis (Phase 4)
Carcinoma (Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Constriction, Pathologic (Phase 4)
Delirium (Phase 3)
Graft vs Host Disease (Phase 2)
Graves Disease (Phase 4)
Head and Neck Neoplasms (Phase 2)
Hepatitis (Phase 4)
Hepatitis A (Phase 4)
Hepatitis B (Phase 4)
Hepatitis, Viral, Human (Phase 4)
Hodgkin Disease (Phase 2)
Hyperthyroidism (Phase 4)
Leukemia (Phase 2)
Leukemia, Myeloid (Phase 2)
Leukopenia (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Multiple Myeloma (Phase 2)
Myelodysplastic Syndromes (Phase 3)
Neoplasms (Phase 2)
Neoplasms, Plasma Cell (Phase 2)
Neuroendocrine Tumors (Phase 2)
Osteoarthritis (Phase 2)
Osteoarthritis, Knee (Phase 2)
Preleukemia (Phase 3)
Prostatic Neoplasms (Phase 3)
Recurrence (Phase 3)
Respiratory Distress Syndrome (Phase 2)
Respiratory Distress Syndrome, Newborn (Phase 2)
Spondylitis (Phase 3)
Spondylitis, Ankylosing (Phase 3)
Syndrome (Phase 3)
Thrombocytopenia (Phase 2)
Waldenstrom Macroglobulinemia (Phase 2)